Control of Tumors by Antigen-Specific CD8⁺ T Cells through PDL1-Targeted Delivery of Antigenic Peptide

Figure 5

In vivo tumor treatment experiment using MC38 tumor-bearing mice treated with either PD-L1-scFv-Fc or PD-L1-scFv-Fc-RE7. (a) Schematic diagram of the experiment. C57BL/6 mice (5 per group) were vaccinated twice with 10 μg pcDNA3-CRTE7 DNA vaccine intramuscularly followed by electroporation at one-week intervals. Vaccinated mice were challenged with MC38 tumor cells one-week postfinal vaccination. Tumor-injected mice were then treated with 30 μg per mouse of PDL1-scfv-Fc-R7, PDL1-scfv-Fc, or no treatment twice at 3-day intervals starting 6 days after MC38 tumor challenge. (b) Kaplan–Meier survival was analyzed in tumor-bearing mice treated with different regimens.

(a)

(b)